SLC5A2 and hydrops fetalis: These findings suggest that as for preventing HF events, SGLT2 inhibitors should be recommended in patients with HF regardless of region, race, baseline NYHA class, and baseline LVEF, and especially in Asian and Black patients with HF and those with NYHA class II.